Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity

Phase 2

Terminated

Conditions: Diabetes Mellitus
Obesity

Interventions: Other: Placebo
Drug: PF-07081532
Drug: Rybelsus

Registration Number: NCT05579977

Lead Sponsor: Pfizer

Brief Summary: The purpose of this study is to find out if PF-07081532 ("the active study drug"), is safe and helps treat people with obesity without diabetes to lose weight, and people with diabetes to keep their blood sugar in good control. Individuals diagnosed with diabetes that are on metformin or individuals with obesity without diabetes will be included in the study.

Those participating in the diabetes part of the study, will receive either active study drug, placebo, or an approved treatment called Rybelsus. Those in the obesity part of the study, will receive either active study drug or placebo. The study will last for about 36 weeks except for the first 25% of the participants that enter in which case the study will last for approximately 48 weeks. during this time there will be visits every 4 weeks with phone calls in between.

Detailed Description: Not available

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 902

Inclusion Criteria

T2DM

T2DM inadequately controlled with metformin
BMI ≥23.0 kg/m2 (≥20.0 kg/m2 in Japan)
HbA1C of 7% to 10% (53-86 mmol/mol)
FPG ≤270 mg/dL (15 mmol/L)

Obesity

BMI ≥30.0 kg/m2
HbA1C ≤6.4% (47 mmol/mol)
FPG ≤126 mg/dL (7 mmol/L)

Exclusion Criteria

Any of the following: Active/current, symptomatic gallbladder disease; History of pancreatitis in the prior 2-months;History of Type 1 Diabetes Mellitus, or secondary forms of diabetes; Any condition affecting drug absorption; Medical history of active liver disease (other than non-alcoholic hepatic steatosis)
Use of pharmacological agents with approved indication for weight loss
T2DM:Use of any agent (other than metformin)for the explicit purpose of glycemic control;History of diabetic ketoacidosis;Proliferative retinopathy or maculopathy requiring acute treatment;
Obesity: Previous or planned weight reduction surgery; Major depressive disorder or other severe psychiatric disorders; Any lifetime history of a suicide attempt; PHQ-9 score ≥15; Response of "yes" to Question 4 or 5, or on any suicidal behavioral question on the C-SSRS
Clinically significant cardiovascular conditions
Uncontrolled blood pressure
Personal or within first-degree relative family history of MTC or MEN2
Other medical or psychiatric condition that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study
Any of the following central lab results: Fasting C-peptide <0.8 ng/mL; ALT or AST ≥2.5x ULN; Direct bilirubin >ULN or T Bili >1.5x ULN except when participants have a history of Gilbert syndrome ; TSH >1.5x ULN or <LLN; Serum calcitonin >ULN; Serum amylase or serum lipase >ULN; eGFR <45 ml/min/1.73 ; Active Hepatitis B, or Hepatitis C; A positive urine drug test for illicit drugs

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo T2DM	Placebo	Placebo daily in T2DM
PF-07081532 40 mg T2DM	PF-07081532	PF-07081532 40 mg daily in T2DM
PF-07081532 80 mg T2DM	PF-07081532	PF-07081532 80 mg daily in T2DM
PF-07081532 260 mg T2DM	PF-07081532	PF-07081532 260 mg daily in T2DM
PF-07081532 20 mg T2DM	PF-07081532	PF-07081532 20 mg daily in T2DM
PF-07081532 160 mg T2DM	PF-07081532	PF-07081532 160 mg daily in T2DM
PF-07081532 140 mg Obesity	PF-07081532	PF-07081532 140 mg daily in Obesity
PF-07081532 200 mg Obesity (Option 1)	PF-07081532	PF-07081532 200 mg daily in Obesity
Rybelsus 14 mg T2DM	Rybelsus	Semaglutide 14 mg daily in T2DM
Placebo Obesity	Placebo	Placebo in Obesity
PF-07081532 200 mg Obesity (Option 2)	PF-07081532	PF-07081532 200 mg daily in Obesity
PF-07081532 260 mg Obesity	PF-07081532	PF-07081532 260 mg daily in Obesity
PF-07081532 80 mg Obesity	PF-07081532	PF-07081532 80 mg daily in Obesity

Primary Outcome Measures

Name	Time	Method
Placebo-adjusted, Change From Baseline in Percentage of Glycated Hemoglobin (HbA1c) at Week 32: Cohort 1 (Type 2 Diabetes Mellitus)	Baseline (result closest prior to dosing on Day 1), Week 32
Placebo-adjusted, Percent Change From Baseline in Body Weight at Week 32: Cohort 2 (Obesity)	Baseline (result closest prior to dosing on Day 1), week 32	Body weight was measured using a calibrated weighing scale.

Secondary Outcome Measures

Name	Time	Method
Percentage of Participants Who Achieved HbA1C <7% at Week 32: Cohort 1 (Type 2 Diabetes Mellitus)	Baseline (result closest prior to dosing on Day 1), Week 32
Percent Change From Baseline in Body Weight at Week 32: Cohort 1 (Type 2 Diabetes Mellitus)	Baseline (result closest prior to dosing on Day 1), Week 32	Body weight was measured using a calibrated weighing scale.
Absolute Change From Baseline in Waist-to-hip Ratio at Week 32: Cohort 2 (Obesity)	Baseline (result closest prior to dosing on Day 1), Week 32	The hip circumference was defined as the circumference around the widest portion of the buttocks. Waist circumference was measured at midpoint, between lower margin of last palpable rib and top of iliac crest (approximately 1 inch \[2.54 cm\] above the navel). The measurements were performed using an anthropometric tape (stretch-resistant).
Number of Participants With Treatment Emergent Adverse Events (TEAEs): Cohort 1 (Type 2 Diabetes Mellitus)	From start of treatment up to minimum of 28 days after last dose of treatment administration (maximum up to Week 28)	An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were any AEs that occurred on or after the first dose of treatment but before the last dose plus lag time.
Change From Baseline in Homeostatic Model Assessment for Insulin Sensitivity (HOMA-S) at Week 32: Cohort 2 (Obesity)	Baseline (result closest prior to dosing on Day 1), Week 32	HOMA-S was calculated as (22.5/\[FPI\] \* FPG) \*100 and measured in terms of percentage sensitivity.
Number of Participants According to Columbia-Suicide Severity Rating Scale (C-SSRS) Category: Cohort 2 (Obesity) Only	Baseline (result closest prior to dosing on Day 1), anytime post-baseline (Up to Week 28)	C-SSRS is an interview-based rating scale to assess suicidal ideation and suicidal behavior and had a binary response (yes/no). C-SSRS data was mapped to C-CASA per Guidance for Industry: Suicidal Ideation and Behavior: Prospective Assessment of Occurrence in Clinical Trials. A participant was said to have suicidal behavior in case of any of following events: 1) completed suicide; 2) suicide attempt; or 3) preparatory acts toward imminent suicidal behavior. A participant showed suicidal ideation if they responded 'yes' to any of the 5 questions, 'Wish to be dead; Non-Specific Active Suicidal Thoughts Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act; active Suicidal Ideation with Some Intent to Act, without Specific Plan; Active Suicidal Ideation with Specific Plan and Intent. The participant was said to exhibit Self-injurious behavior, no suicidal intent if they responded as Yes to 'Has participant engaged in Non-suicidal Self-Injurious Behavior
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 32: Cohort 1 (Type 2 Diabetes Mellitus)	Baseline (result closest prior to dosing on Day 1), Week 32
Number of Participants With Serious Adverse Events (SAEs): Cohort 2 (Obesity)	From start of treatment up to minimum of 28 days after last dose of treatment administration (maximum up to Week 28)	SAE defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); resulted in congenital anomaly/birth defect; was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic; other important medical events.
Number of Participants With Vital Sign Abnormalities: Cohort 1 (Type 2 Diabetes Mellitus)	Up to week 28	Vital signs included blood pressure and pulse rate and were measured with the participants in a seated position after at least 5 minutes of rest for the participant. Criteria for abnormalities included: Systolic Blood Pressure (millimeter of mercury \[mmHg\]): value more than (\>) 200 and value less than (\<) 90; Diastolic blood pressure: value \> 100 and \< 40; Pulse rate: (beats per minute \[BPM\]): value \< 40 and \> 110.
Number of Participants With Clinical Laboratory Abnormalities: Cohort 2 (Obesity)	Up to week 28	Hematology: platelets (10\^9/L)\< 0.5\* LLN; leukocytes\< 0.6\LLN and \>1.5\ULN; lymphocytes and neutrophils \<0.8\LLN and \>1.2\ULN; basophils, eosinophils, monocytes:\>1.2\ULN; prothrombin time (sec) \>1.1\ULN; prothrombin international normalized ratio \>1.1\ULN; clinical chemistry: bilirubin (mg/dL), indirect bilirubin:\>1.5\ULN; aspartate and alanine aminotransferase, gamma glutamyl transferase (U/L):\>3.0\ULN; urea nitrogen and creatinine (mg/dL)\>1.3\ ULN;HDL cholesterol (mg/dL)\<0.8\LLN; LDL (mg/dL)\>1.2\ULN, Triglycerides (mg/dL):\>1.3\ULN; Potassium (milliequivalents per liter) \< 0.9\LLN and \> 1.1\* ULN; calcium (mg/dL)\< 0.9\LLN, Thyroxine (nanograms/dL\<0.8\LLN and \>1.2\ULN, HbA1C (%)\>1.3\ULN; Amylase, Lipase (U/L) and Glucose -Fasting (mg/dL)\>1.5\*ULN; urinalysis: pH\> 8; urine glucose, ketones, protein, hemoglobin, nitrite and leukocyte esterase\>=1. Number of participants with abnormalities in any of the laboratory parameters is reported.
Placebo-adjusted, Change From Baseline in HbA1C in the Rybelsus Arm at Week 32: Cohort 1 (Type 2 Diabetes Mellitus)	Baseline (result closest prior to dosing on Day 1), Week 32	This outcome measure was planned to be analyzed only for rybelsus arm and placebo arm as pre-specified in the protocol.
Percentage of Participants Achieving >=5%, >=10%, and >=15% Body Weight Loss at Week 32 Relative to Baseline: Cohort 2 (Obesity)	Baseline (result closest prior to dosing on Day 1), Week 32
Absolute Change From Baseline in Waist Circumference at Week 32: Cohort 2 (Obesity)	Baseline (result closest prior to dosing on Day 1), Week 32	Waist circumference was measured at midpoint, between lower margin of last palpable rib and top of iliac crest (approximately 1 inch \[2.54 centimeter {cm}\] above the navel). It was measured by using an anthropometric tape (stretch-resistant).
Change From Baseline in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) at Week 32: Cohort 2 (Obesity)	Baseline (result closest prior to dosing on Day 1), Week 32	HOMA-IR was calculated as: fasting plasma insulin (\[FPI\]\(FPG)/405 and measured in terms of mg/dL\ (milliunits per liter).
Number of Participants Reporting Adverse Events Leading to Permanent Discontinuation From Study Treatment and Study: Cohort 1 (Type 2 Diabetes Mellitus)	From start of treatment up to minimum of 28 days after last dose of treatment administration (maximum up to Week 28)	\\ An AE was any untoward medical occurrence in a participants or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs leading to permanent discontinuation from study were those with an AE record indicating the AE caused permanent discontinuation from the study. AEs leading to permanent discontinuation from study treatment were those AEs with an AE record indicating that action taken with study treatment was drug withdrawn but AE did not cause the participant to be discontinued from study.
Number of Participants With Hypoglycemic Adverse Events (HAE) According to Titration Dose: Cohort 1 (Type 2 Diabetes Mellitus)	Up to week 28	Glucose values were monitored using glucometer. Hypoglycemia =plasma/blood glucose value of \<70 mg/dL (3.9 millimoles per liter \[mmol/L\]). Severe HAE: Participant was unable to treat him/herself due to neurological impairment (not age) and required assistance of another person, at least one neurological symptom of memory loss, confusion, uncontrolled behavior etc. Either documented blood glucose\<=54 mg/dL (2.7 mmol/L). Documented symptomatic: An event during which symptoms of HAE were accompanied with plasma/blood glucose \<70 mg/dL and prompt resolution with food intake, SC glucagon, or IV glucose. Probable symptomatic HAE: An event during which symptoms of an HAE were not accompanied by a plasma glucose determination but was presumably caused by a plasma glucose concentration \<70 mg/dL and prompt resolution with food intake, SC glucagon, or IV glucose. Asymptomatic: An event not accompanied by typical symptoms of an HAE, but a plasma/blood glucose value of \<70 mg/dL was reported.
Number of Participants With Hypoglycemic Adverse Events According to Titration Dose: Cohort 2 (Obesity)	Up to week 28	Glucose values were monitored using glucometer. Hypoglycemia =plasma/blood glucose value of \<70 mg/dL (3.9 mmol/L). Severe HAE: Participant was unable to treat him/herself due to neurological impairment (not age) and required assistance of another person, at least one neurological symptom of memory loss, confusion, uncontrolled behavior etc. Either documented blood glucose\<=54 mg/dL (2.7 mmol/L). Documented symptomatic: An event during which symptoms of HAE were accompanied with plasma/blood glucose \<70 mg/dL u and prompt resolution with food intake, SC glucagon, or IV glucose. Probable symptomatic HAE: An event during which symptoms of an HAE were not accompanied by a plasma glucose determination but was presumably caused by a plasma glucose concentration \<70 mg/dL and prompt resolution with food intake, SC glucagon, or IV glucose. Asymptomatic: An event not accompanied by typical symptoms of an HAE, but a plasma/blood glucose value of \<70 mg/dL was reported.
Number of Participants With Treatment Emergent Adverse Events (TEAEs): Cohort 2 (Obesity)	From start of treatment up to minimum of 28 days after last dose of treatment administration (maximum up to Week 28)	An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were any AEs that occurred on or after the first dose of treatment but before the last dose plus lag time.
Number of Participants With Serious Adverse Events (SAEs): Cohort 1 (Type 2 Diabetes Mellitus)	From start of treatment up to minimum of 28 days after last dose of treatment administration (maximum up to Week 28)	SAE defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); resulted in congenital anomaly/birth defect; was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic; other important medical events.
Number of Participants With Vital Sign Abnormalities: Cohort 2 (Obesity)	Up to week 28	Vital signs included blood pressure and pulse rate and were measured with the participants in a seated position after at least 5 minutes of rest for the participant. Criteria for abnormalities included: Systolic blood pressure (mmHg): value \> 200 and value \< 90; Diastolic blood pressure: value \> 100 and \< 40; Pulse rate: (BPM): value \< 40 and \> 110.
Number of Participants With Clinical Laboratory Abnormalities: Cohort 1 (Type 2 Diabetes Mellitus)	Up to week 28	Hematology: platelets (10\^9/L)\< 0.5\lower limit of normal (LLN); leukocytes\< 0.6\LLN and \>1.5\upper limit of normal (ULN); lymphocytes and neutrophils \<0.8\LLN and \>1.2\ULN; basophils, eosinophils, monocytes:\>1.2\ULN; prothrombin time (sec) \>1.1\ULN; prothrombin international normalized ratio \>1.1\ULN; clinical chemistry: bilirubin (mg/dL), indirect bilirubin:\>1.5\ULN; aspartate and alanine aminotransferase, gamma glutamyl transferase (U/L):\>3.0\ULN; urea nitrogen and creatinine (mg/dL)\>1.3\* ULN;HDL cholesterol (mg/dL)\<0.8\LLN; LDL (mg/dL)\>1.2\ULN, Triglycerides (mg/dL):\>1.3\ULN; Potassium (milliequivalents per liter) \< 0.9\LLN and \> 1.1\* ULN; calcium (mg/dL)\< 0.9\LLN, Thyroxine (nanograms/dL\<0.8\LLN and \>1.2\ULN, HbA1C (%)\>1.3\ULN; Amylase, Lipase (U/L) and Glucose -Fasting (mg/dL)\>1.5\*ULN; urinalysis: pH\> 8; urine glucose, ketones, protein, hemoglobin, nitrite and leukocyte esterase\>=1. Number of participants with abnormalities in any of the laboratory parameters is reported.
Number of Participants Reporting Adverse Events Leading to Permanent Discontinuation From Study Treatment and Study: Cohort 2 (Obesity)	From start of treatment up to minimum of 28 days after last dose of treatment administration (maximum up to Week 28)	An AE was any untoward medical occurrence in a participants or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs leading to permanent discontinuation from study were those with an AE record indicating the AE caused permanent discontinuation from the study. AEs leading to permanent discontinuation from study treatment were those AEs with an AE record indicating that action taken with study treatment was drug withdrawn but AE did not cause the participant to be discontinued from study.
Number of Participants With ECG Abnormalities: Cohort 1 (Type 2 Diabetes Mellitus)	Up to week 28	Standard 12-lead ECGs were performed after the participant had rested quietly for more than 10 minutes in a supine position utilizing an ECG machine that automatically calculated the heart rate and measured PR interval, QT interval, QT interval corrected using Fridericia's formula (QTcF), and QRS complex. ECG abnormalities were categorized as: PR interval (milliseconds \[msec\]), Value \>= 300; percent change (%Chg) greater than equal (\>=) 25/50%. QRS duration (msec): Value \>= 140 and %Chg \>= 50%. QT interval (msec): Value \> 500; QTCF interval (msec): 450 \< Value \<= 480, 480 \< Value \<= 500, Value \> 500; 30 \<= Change (Chg) \<= 60; Chg \> 60.
Number of Participants With ECG Abnormalities: Cohort 2 (Obesity)	Up to week 28	Standard 12-lead ECGs were performed after the participant had rested quietly for more than 10 minutes in a supine position utilizing an ECG machine that automatically calculated the heart rate and measured PR interval, QT interval, QTcF, and QRS complex. ECG abnormalities were categorized as: PR interval msec, Value \>= 300; percentage change (%Chg) \>= 25/50%. QRS duration (msec): Value \>= 140 and %Chg \>= 50%. QT interval (msec): Value \> 500; QTCF interval (msec): 450 \< Value \<= 480, 480 \< Value \<= 500, Value \> 500; 30 \<= Change (Chg) \<= 60; Chg \> 60.

Trial Locations

Locations (86): LMC Clinical Research Inc. (Bayview)
🇨🇦
Toronto, Ontario, Canada
San Fernando Valley Health Institute
🇺🇸
Canoga Park, California, United States
Catalina Research Institute, LLC
🇺🇸
Montclair, California, United States
University Clinical Investigators, Inc.
🇺🇸
Tustin, California, United States
Preferred Primary Care Physicians
🇺🇸
Uniontown, Pennsylvania, United States
Medical Colleagues of Texas, LLP
🇺🇸
Katy, Texas, United States
"Prevencia - 2000 - Medical Center for Prehospital Medical Care" OOD
🇧🇬
Stara Zagora, Bulgaria
Fukuwa Clinic
🇯🇵
Chuo-ku, Tokyo, Japan
Mercury Street Medical Group, PLLC
🇺🇸
Butte, Montana, United States
Adult Medicine of Lake County
🇺🇸
Mount Dora, Florida, United States
Premier Research
🇺🇸
Trenton, New Jersey, United States
Aggarwal and Associates Limited
🇨🇦
Brampton, Ontario, Canada
Oświęcimskie Centrum Badań Klinicznych
🇵🇱
Oświęcim, Małopolskie, Poland
GCM Medical Group, PSC - Hato Rey Site
🇵🇷
San Juan, Puerto Rico
Milestone Research Inc.
🇨🇦
London, Ontario, Canada
Healthstar Physicians
🇺🇸
Morristown, Tennessee, United States
Innovative Research of West Florida
🇺🇸
Clearwater, Florida, United States
Centrum Badan Klinicznych PI-House sp. z o.o.
🇵🇱
Gdansk, Pomorskie, Poland
Gabinet Lekarski Małgorzata Jadwiga Saryusz-Wolska
🇵🇱
Łódź, Poland
Jacksonville Center for Clinical Research
🇺🇸
Jacksonville, Florida, United States
Manna Research Mirabel
🇨🇦
Mirabel, Quebec, Canada
HealthStar Physicians, P.C.
🇺🇸
Morristown, Tennessee, United States
Anderson Medical Research
🇺🇸
Fort Washington, Maryland, United States
KO-MED Centra Kliniczne Pulawy
🇵🇱
Pulawy, Lubelskie, Poland
Bluewater Clinical Research Group Inc.
🇨🇦
Sarnia, Ontario, Canada
Meridian Clinical Research, LLC
🇺🇸
Cincinnati, Ohio, United States
Northeast Clinical Research of San Antonio
🇺🇸
San Antonio, Texas, United States
Anaheim Clinical Trials, LLC
🇺🇸
Anaheim, California, United States
Empire Clinical Research
🇺🇸
Pomona, California, United States
Evanston Premier Healthcare Research LLC
🇺🇸
Skokie, Illinois, United States
Diablo Clinical Research, Inc.
🇺🇸
Walnut Creek, California, United States
Iowa Diabetes and Endocrinology Research Center
🇺🇸
West Des Moines, Iowa, United States
StudyMetrix Research
🇺🇸
Saint Peters, Missouri, United States
Medication Management
🇺🇸
Greensboro, North Carolina, United States
Heritage Valley Multispecialty Group, Inc
🇺🇸
Beaver, Pennsylvania, United States
Preferred Primary Care Physicians, Preferred Clinical Research (Ofc 18)
🇺🇸
Pittsburgh, Pennsylvania, United States
Velocity Clinical Research, Providence
🇺🇸
East Greenwich, Rhode Island, United States
Velocity Clinical Research, Dallas
🇺🇸
Dallas, Texas, United States
Elligo Clinical Research Center
🇺🇸
Austin, Texas, United States
UT Southwestern Medical Center
🇺🇸
Dallas, Texas, United States
Consano Clinical Research, LLC
🇺🇸
Shavano Park, Texas, United States
Southwest Internal Medicine
🇺🇸
Saint George, Utah, United States
Sugar Lakes Family Practice
🇺🇸
Sugar Land, Texas, United States
Chrysalis Clinical Research
🇺🇸
Saint George, Utah, United States
Medical Centre "Asklepiy"
🇧🇬
Dupnitsa, Kyustendil, Bulgaria
Manassas Clinical Research Center
🇺🇸
Manassas, Virginia, United States
MHAT Botevgrad
🇧🇬
Botevgrad, Sofia, Bulgaria
G A Research Associates
🇨🇦
Moncton, New Brunswick, Canada
Medical Center Zdrave 1
🇧🇬
Kozloduy, Vratsa, Bulgaria
Dr. M.B. Jones Inc.
🇨🇦
Victoria, British Columbia, Canada
Dawson Clinical Research
🇨🇦
Guelph, Ontario, Canada
Diex Recherche Quebec Inc.
🇨🇦
Quebec, Canada
Centre de Recherche Saint-Louis
🇨🇦
Quebec, Canada
Kardiologicka a Angiologicka Ambulance
🇨🇿
Ostrava, Ostrava Město, Czechia
Agentura Science Pro
🇨🇿
Olomouc, Czechia
MUDr. Alena Vachova
🇨🇿
Ceske Budejovice, Jihočeský KRAJ, Czechia
Private Practice - Dr. Tomáš Brychta
🇨🇿
Olomouc, Czechia
Clinical Trials Service s.r.o.
🇨🇿
Uherske Hradiste, Czechia
Borbánya Praxis
🇭🇺
Nyíregyháza, Borbánya, Szabolcs-szatmár-bereg, Hungary
CLINFAN Szolgáltató Kft
🇭🇺
Szekszárd, Tolna, Hungary
EUC Klinika Praha
🇨🇿
Prague, Czechia
ClinDiab Kft.
🇭🇺
Budapest, Hungary
Debreceni Egyetem Klinikai Kozpont
🇭🇺
Debrecen, Hungary
Belinus Orvosi és Számitástechnikai Bt
🇭🇺
Debrecen, Hajdú-bihar, Hungary
DRC Gyógyszervizsgáló Központ
🇭🇺
Balatonfüred, Veszprém, Hungary
Nakakinen clinic
🇯🇵
Naka, Ibaraki, Japan
Shiraiwa Medical Clinic
🇯🇵
Kashiwara, Osaka, Japan
Medical Corporation Chiseikai Tokyo Center Clinic
🇯🇵
Chuo-ku, Tokyo, Japan
Medical Corporation Heishinkai OCROM Clinic
🇯🇵
Suita-shi, Osaka, Japan
Seiwa Clinic
🇯🇵
Adachi-ku, Tokyo, Japan
Medical Corporation Heishinkai ToCROM Clinic
🇯🇵
Shinjuku-ku, Tokyo, Japan
Tokyo-Eki Center-building Clinic
🇯🇵
Chuo-ku, Tokyo, Japan
Zdrowie Osteo-Medic
🇵🇱
Bialystok, Podlaskie, Poland
Centrum Zdrowia Metabolicznego Pawel Bogdanski
🇵🇱
Poznan, Poland
NZOZ Przychodnia Specjalistyczna Andrzej Wittek, Henryk Rudzki
🇵🇱
Ruda Slaska, Śląskie, Poland
Latin Clinical Trial Center
🇵🇷
San Juan, Puerto Rico
Trinity Clinical Research
🇺🇸
Centreville, Alabama, United States
Endocrine Research Solutions, Inc.
🇺🇸
Roswell, Georgia, United States
Cedar Crosse Research Center
🇺🇸
Chicago, Illinois, United States
Alliance for Multispecialty Research, LLC
🇺🇸
Norman, Oklahoma, United States
Hassman Research Institute
🇺🇸
Berlin, New Jersey, United States
Tapia Internal Medicine Clinic
🇺🇸
Paris, Texas, United States
Diagnostic Consultative Center Aleksandrovska
🇧🇬
Sofia, Sofia (stolitsa), Bulgaria
Diex Recherche Victoriavile Inc.
🇨🇦
Victoriaville, Quebec, Canada
EDUMED s.r.o.
🇨🇿
Broumov, Kralovehradecky KRAY, Czechia
Yokohama Minoru Clinic
🇯🇵
Yokohama, Japan